top of page
LogoWix.jpg
Search

Regenerative Research Roundup — August 2026

Welcome to the Regenerative Research Roundup, where we look through recently published research and bring you the best of the best in a quick-to-read digest.


This month, we explore:

  • A Level I network meta-analysis of 24 RCTs concluding no orthobiologic beats HA by a clinically meaningful margin

  • 3,667 knee OA patients, where income, employment and distance to care predicted who received PRP

  • 23 international experts agreeing on 10 post-PRP rehabilitation recommendations

  • High molecular weight HA lowering inflammatory and catabolic markers in-vitro


Let's dive in!


Intra-articular Orthobiologics Show Statistically but Not Clinically Meaningful Improvements Compared With Viscosupplementation in Knee Osteoarthritis: A Network Meta-analysis of Randomized Controlled Trials


Arthroscopy // LOE: I


Network meta-analysis of 24 RCTs (n=2,960), consisting of all LOE: 1, comparing intra-articular PRP, adipose-derived stromal vascular fraction (SVF), bone marrow aspirate concentrate (BMAC), and umbilical cord-derived MSCs against hyaluronic acid.  Pain and function scores were standardized by dividing each trial’s mean change by a published minimal clinically important difference (MCID), then pooled at 3, 6, and 12 months with SUCRA rankings.  MRI and safety findings were summarized narratively.


Key Findings:

  • At 12 months all four orthobiologics beat HA on pain and function with statistical significance with SVF having the largest gap and PRP the smallest

  • The authors’ conclusion is that none of the four orthobiologics surpassed HA by one MCID unit at any timepoint through 12 months

  • SUCRA ranked SVF first for pain and function at 12 months, while PRP ranked lowest of the four orthobiologics, ahead only of HA

 

Clinical Perspective:


The implication with the study is that PRP doesn't have a meaningful step-up in patient outcomes compared to HA. So why give PRP at all? Given the number of studies showing PRP superiority, that depends entirely on how "meaningful" was defined.


The VAS threshold Han and team used was developed on an individual-level responder threshold;  did a particular patient improve by at least 19.1 mm? They applied it to the difference between group averages instead. Those aren't the same measurements;  compare averages and the gap looks small, but compare responders and PRP could be sitting further ahead. The design just doesn't really tell us.


The WOMAC and KOOS thresholds carry a transferability problem of their own.  Both came from Kim et al., 2021 and Jacquet et al., 2020, measuring outcomes 2 years after high tibial osteotomy, not 3-12 months post an intra-articular injection. 


When dose was actually measured, the MRI findings favour PRP over HA.  Lisi et al., 2018 found more patients gaining a full cartilage grade on PRP than HA.   Likewise, Bansal et al., 2021, delivering a measured 10.45 billion platelets, found no thickness gain in either arm, but thickness held steady in 82.8% of PRP patients versus 61.7% on HA.  



Health Disparities in Orthobiologics: Factors Influencing Access to Platelet-Rich Plasma for Knee Osteoarthritis


Orthopaedic Journal of Sports Medicine // LOE: III


Cross-sectional analysis of 3,667 knee OA patients across all Mayo Clinic locations and Detroit Medical Center (2022–2023), comparing PRP recipients against a randomly sampled standard-care control group.  Logistic regression and random forest models were trained on demographic, socioeconomic, insurance and geographic variables, with OA severity graded from clinical notes by a validated NLP algorithm.


Key Findings:

  • Upper-middle income nearly doubled the odds of receiving PRP, while retirement reduced them by 49% and disability by 84%

  • Distance to care was substantially higher for the PRP group with a median distance of 62 miles, as opposed to 31 miles in the standard group

  • PRP costing between $175 and $4,973, covered neither by Medicare nor Medicaid, nor by most private insurers


Clinical Perspective:


What decided who got PRP wasn't clinical, patients with severe knee OA were just as likely as those with mild knee OA. Distance to care ended up being the strongest predictor with patients traveling twice as far to get PRP, because PRP is almost exclusively concentrated at specialized sites.


Younger patients sought PRP out more, with each year lowering the odds by 4%.  Unsurprisingly, upper-middle doubled the odds compared to the middle class, as they can absorb any of the out-of-pocket costs that come with treatments not covered by private or public insurance. 



Rehabilitation and return to activity after platelet-rich plasma injections in chronic tendinopathies: Consensus from international experts


PM&R // LOE: V


Expert-consensus on return-to-activity post PRP injection, following the French health authority’s recommendations-by-consensus methodology.  A pilot group of three GRIIP physicians practicing in Belgium, Canada and Switzerland generated 14 propositions from a MEDLINE review of post-PRP rehabilitation protocols for chronic tendinopathy, which were then submitted to a panel of 23 experts across five countries.


Key Findings:

  • Experts strongly agree NSAIDs should be avoided for the first few weeks after a PRP injection for chronic tendinopathy

  • Experts strongly agree tendon rehabilitation should be started quickly (after 5–10 days) after an intratendinous injection of PRP for chronic tendinopathy

  • Experts agree rehabilitation after intratendinous injection of PRP should include sub-painful isometric work (VAS ≤3/10 during and for 24 h after the session)

  • Experts strongly agree a second injection may be suggested in case of partial improvement after 3 months


Clinical Perspective:


These four recommendations map out a useful in-clinic practices for return-to-play timeline in tendinopathy.   Avoid NSAIDs, so platelets can properly degranulate in the system.  Within 5 to 10 days, start loading the tendon appropriately to accelerate the repair process and increase tissue regeneration.  Finally, give rehab a full 3 months before considering a second injection.  This study doesn’t serve to replace existing rehab protocols, instead it slots PRP in as the catalyst within an existing protocol. 



Effects of high-molecular-weight hyaluronic acid on inflammatory and matrix-associated responses in a chondrocyte–osteoclast co-culture model


Journal of Orthopaedic Surgery and Research // LOE: V


In vitro study evaluating the effects of crosslinked high-molecular weight Hyaluronic acid (HMW HA) on the osteoarthritic microenvironment, modelled using the chondrocyte-osteoclastm co-culture model.  MSC-derived chondrocytes and osteoclast-like cells (RAW 264.7, M-CSF/RANKL-driven) were co-cultured 1:1, stressed with lipopolysaccharide (LPS), then treated with HMW HA (>1 MDa) across 50–500 µg/mL for 24–48 hours.  Cell viability was assessed, and inflammatory markers were analysed by Western blot, qPCR, ELISA.


Key Findings:


  • HMW HA-treated cultures showed lower NF-κB p65, IL-1β, TNF-α, MMP-13 and ADAMTS-5, alongside higher COL2A1 and ACAN

  • HMW HA improved metabolic activity and preserved cell morphology in a dose-dependent manner, plateauing at 200–500 µg/mL

 

Clinical Perspective:


HA lowered inflammatory and catabolic markers here, which is consistent with what's already been reported. What caught my attention is what wasn't measured: the study never looked at whether the HA chain holds up in a joint environment under oxidative stress.


That's where Mongkhon et al. (2014) is a more useful read. Using primary human OA chondrocytes stressed with IL-1β or H₂O₂, they tested HA/sorbitol against sorbitol alone.  Mongkhon and team traced the antioxidant effect primarily to sorbitol and the anti-inflammatory/anti-catabolic effect primarily to HA.  Two components, two roles, both playing a complementary part in the OA joint environment.


 
 
 

Comments

bottom of page